Non-resectable Stage IIIa-b lung carcinoma: a Phase II study on continuous infusion of cisplatin and concurrent radiotherapy (plus adjuvant surgery)

Amedeo V. Bedini, Luca Tavecchio, Franco Milani, Alberto Gramaglia, Carlo Spreafico, Alfonso Marchianò, Gianluigi Ravasi

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-eight patients with non-resectable non-small-cell Stage IIIa-b lung cancer were treated in a Phase II study with radiotherapy (50 Gy in a 25-fraction split-course) plus concurrent continuous infusion of cisplatin given at a daily dose of 6 mg/m2, with the aim of investigating its radiopotentiation properties. Treatments were given on an outpatient basis by means of a central venous catheter and a portable pump. Adjuvant surgery was undertaken when feasible. Toxicity was mild to moderate. The probability of a partial or complete locoregional response at 4 weeks after treatment completion was 83% (confidence limits at 95%: 13). Eighteen patients were resected. Overall 1-, 2- and 3-year progression-free survival probabilities were 42, 24 and 21%. These figures were 63, 37 and 24% in observed survival curves. Patients with squamous-cell tumors had observed survival rates of 82, 50 and 28% at 1, 2 and 3 years, compared to 42, 19 and 19% in patients with non-squamous histology. The high response and survival rates obtained at a low price according to toxicity require further investigation.

Original languageEnglish
Pages (from-to)73-84
Number of pages12
JournalLung Cancer
Volume10
Issue number1-2
DOIs
Publication statusPublished - 1993

Keywords

  • Adjuvant surgery
  • Cisplatin
  • Continuous infusion
  • Non-small-cell lung cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Non-resectable Stage IIIa-b lung carcinoma: a Phase II study on continuous infusion of cisplatin and concurrent radiotherapy (plus adjuvant surgery)'. Together they form a unique fingerprint.

Cite this